HMN 2025: How Pfizer ends testing of weight problems capsule after doable liver harm

Pfizer has stopped creating a once-daily capsule to deal with weight problems after an individual in a medical trial confirmed indicators of a doable liver harm.

The firm stated the harm went away after the particular person stopped taking the drug, referred to as danuglipron, The Associated Press reported.

The capsule was in early testing to assist decide the very best dose, in response to a Pfizer spokeswoman.

The firm had deliberate to maneuver the drug into late-stage trials, sometimes the ultimate step earlier than evaluate by the U.S. Food and Drug Administration (FDA).

Pfizer will now cease all testing of danuglipron, together with its use with different medication for weight problems therapy. However, the corporate stated it nonetheless plans to work on different weight problems remedies which are in earlier phases of analysis.

Obesity medication have turn out to be a significant focus for pharmaceutical corporations. Injectable remedies like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy have introduced in billions in income. Zepbound earned almost $5 billion in 2024 alone, The Associated Press reported.

But these medication have to be injected, which some of us do not need to do.

As a consequence, drugmakers have been racing to develop capsule variations. Lilly expects to launch new knowledge this 12 months on two oral weight problems medication it’s finding out.

While demand for these remedies is excessive, entry has been a difficulty. Some sufferers face insurance coverage points or excessive out-of-pocket prices.

Even with current value cuts, many of those medicines nonetheless price lots of of {dollars} per thirty days.

Pfizer had already stopped testing of a twice-daily model of danuglipron in late 2023 after greater than half the folks in a trial stopped taking it.

© 2025 .